Close

News

Pharmapack Moves to May 2021

Pharmapack Europe, organised by Informa Markets, moves to May 2021 (19-20) to provide attendees, exhibitors and the pharma packaging community the best season and format. The decision follows a careful review with key stakeholders, with the exhibition continuing at...

FDA Grants Emergency Use Authorization for Eli Lilly, Sandia National Labs Coronavirus PCR Tests

The US FDA granted separate Emergency Use Authorizations for PCR-based SARS-CoV-2 tests developed by Eli Lilly and Sandia National Laboratories. The Lilly SARS-CoV-2 Assay is designed to detect the virus' nucleocapsid gene in nasopharyngeal, oropharyngeal, anterior nasal, and midturbinate swabs,...

European Union signs Remdesivir deal with Gilead

The European Union's executive said that it has signed a contract with Gilead for its COVID-19 medicine remdesivir that would cover 30,000 patients in the bloc from early August. "The Commission signed a contract with the pharmaceutical company Gilead for...

AstraZeneca’s Calquence Receives Positive CHMP Opinion For Chronic Blood Cancer

AstraZeneca’s Calquence has been recommended for marketing authorisation in the EU for the treatment of adult patients with chronic lymphocytic leukaemia (CLL), the most common type of leukaemia in adults. The Committee for Medicinal Products for Human Use (CHMP) of...

US to invest $472 million more in Moderna to speed up vaccine process

Moderna has unveiled a modification to its contract with the Biomedical Advanced Research and Development Authority (BARDA) for an additional commitment of up to $472 million to support late stage clinical development including the expanded Phase 3 study of...

LGM Pharma Acquires Pharmaceutical Development and Manufacturing Unit of Nexgen Pharma

LGM Pharma announced that it has acquired the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. The combination brings together LGM Pharma’s global leadership in Active Pharmaceutical Ingredient (API) sourcing, distribution and supply chain management...

Samsung Biologics Expands Drug Product Manufacturing Facility in Incheon

Samsung Biologics (207940.KS) announced a plan to expand its Drug Product (DP) capability in line with increasing market demand and to ensure flexible production capabilities for new and existing clients. Samsung Biologics has been providing aseptic filling and lyophilization services...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read